BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38618727)

  • 1. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
    Qadir MI; Ahmed B; Hussain N
    Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
    Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
    Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease.
    Turturro F; Arnold MD; Frist AY; Seth P
    Leuk Lymphoma; 2002 Jun; 43(6):1323-8. PubMed ID: 12153002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.
    Trieu Y; Wen XY; Skinnider BF; Bray MR; Li Z; Claudio JO; Masih-Khan E; Zhu YX; Trudel S; McCart JA; Mak TW; Stewart AK
    Cancer Res; 2004 May; 64(9):3271-5. PubMed ID: 15126369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
    Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
    Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Hodgkin's disease.
    Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
    Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Majolino I; Pearce R; Taghipour G; Goldstone AH
    J Clin Oncol; 1997 Feb; 15(2):509-17. PubMed ID: 9053472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.
    Laurence AD; Goldstone AH
    Semin Hematol; 1999 Jul; 36(3):303-12. PubMed ID: 10462330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment and immunotherapy of Hodgkin's lymphoma.
    Klimm B; Schnell R; Diehl V; Engert A
    Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PA
    Cancer J; 2005; 11(5):425-31. PubMed ID: 16259874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
    Rooney CM; Roskrow MA; Suzuki N; Ng CY; Brenner MK; Heslop H
    Ann Oncol; 1998; 9 Suppl 5():S129-32. PubMed ID: 9926252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
    Sarris AH; Luthra R; Papadimitracopoulou V; Waasdorp M; Dimopoulos MA; McBride JA; Cabanillas F; Duvic M; Deisseroth A; Morris SW; Pugh WC
    Blood; 1996 Sep; 88(5):1771-9. PubMed ID: 8781434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
    Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
    Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.